Topics:

Commentary (Green/Hortobagyi): Improvements in Tumor Targeting, Survivorship, and Chemoprevention Pioneered by Tamoxifen

Commentary (Green/Hortobagyi): Improvements in Tumor Targeting, Survivorship, and Chemoprevention Pioneered by Tamoxifen

Historically, antiestrogen therapy in the form of oophorectomy was among the first treatments that took advantage of the differential influences of growth and proliferation that exist between cancer cells and most normal tissue.[1] The clinical observations of the 19th century have been translated into one of the most effective cancer treatment strategies in history. First identified as a potential "morning after pill," tamoxifen is now the most widely utilized anticancer medication prescribed worldwide.

Rather than simply presenting important milestones in the development of endocrine therapy, Dr. Craig Jordan elegantly reviews the history of the development of endocrine therapy from a clinical, laboratory, and societal perspective. His contributions to the field are well documented and reflected in his article. The author highlights many of the obstacles faced in the development of endocrine therapy. In addition, he correlates discoveries and observations made in the laboratory that were also reflected in the clinical use of endocrine therapy.

The saying "timing is everything" surely applies to the development and use of tamoxifen. This medication was discovered to be an active treatment of advanced breast cancer before its target, the estrogen receptor, was truly known. Hand in hand with the identification and cloning of the estrogen receptor came the understanding of tamoxifen's mechanism of action and the agent's increased use.

 

Evolution of Drug Trials

Tamoxifen's clinical development was also instrumental in molding the way clinical studies were conducted. The original randomized clinical studies evaluating the use of tamoxifen in the late 1970s demonstrated a disease-free survival benefit when used as adjuvant therapy.[2,3] Most studies did not have sufficient power to consistently demonstrate an improvement in survival, and it was not until the Early Breast Cancer Trialists’ Collaborative Group meta-analysis was conducted that the benefit became clear: Adjuvant tamoxifen reduced the risk of recurrence and death for women with breast cancer.[4] The evaluation of tamoxifen in underpowered studies highlighted the need for large randomized clinical trials to demonstrate benefits in outcome, so that promising therapies are not shelved due to limitations in study design.

 

Clinical Observations

Dr. Jordan's review also highlights how the use of the right preclinical model can assist in the development of a lifesaving drug. Tamoxifen was shown to prevent the development and progression of breast cancer in animal models. However, the clinical observation that tamoxifen reduces the risk of new breast cancers in patients treated with tamoxifen was just as relevant in moving this agent into the prevention setting as were the preclinical models. Clinical observations regarding the use of tamoxifen continue to guide laboratory-based research and vice versa.

For example, tamoxifen is associated with several unfavorable side effects, in part due to its estrogen-agonist action. Development of newer selective estrogen receptor modulators will potentially allow an enhanced therapeutic index with decreased toxicity.[5] In addition, despite high levels of estrogen receptor expression, some cancers are inherently resistant to tamoxifen or develop resistance to tamoxifen after prolonged exposure to the agent. Ongoing research focuses on identifying mechanisms of endocrine resistance.[6] This investigation will hopefully lead to targeted drug development that will restore or establish sensitivity to antiestrogen agents.

 

Aromatase Inhibitors

The hypothesis that an "estrogen-free" environment would lead to control of breast cancer was driven not only by the clinical experience with oophorectomy and older aromatase inhibitors but also by the clinical benefits and estrogen-agonist toxicities of tamoxifen. The ultimate goal of this therapeutic approach was the ability to reduce estrogen levels in breast tissue and breast cancer without having any agonist effects on the uterus or liver.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.